Executives On The Move: Harbour BioMed Gets New Chief Strategy Officer From BMS
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
More from Executives On The Move
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
Recent moves in the industry include C-suite changes at Ironwood Pharmaceuticals and Procaps Group, plus Viracta Therapeutics acquires chief executive officer from Molecular Templates.
Recent moves in the industry include changes at the top at Shanghai Bao Pharmaceutical and Alumis, plus Nurix Therapeutics acquires chief commercial officer from Arvinas.
Recent moves in the industry include C-suite changes at Ribometrix and Emyria, plus Arvinas acquires chief commercial officer from Lexicon Pharmaceuticals.
More from Scrip
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.